Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Perforation-I: Introduction01:22

Esophageal Perforation-I: Introduction

183
Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
183
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

154
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
154
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

718
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
718

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standalone versus combined preserflo MicroShunt surgery: A two-year controlled cohort study.

Eye (London, England)·2026
Same author

Three-year clinical outcomes of PRESERFLO MicroShunt implantation in eyes with previous failed trabeculectomy.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Is the interventional glaucoma paradigm reflected in real-world practice? Insights from iStent combined with cataract surgery (2010-2022).

European journal of ophthalmology·2026
Same author

Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Topical Losartan in Ophthalmology: Rationale, Experimental and Clinical Evidence, and Emerging Clinical Applications.

Journal of clinical medicine·2026
Same author

Sectorial iris atrophy as the first manifestation of 13q deletion syndrome.

Journal francais d'ophtalmologie·2026

Related Experiment Video

Updated: Sep 19, 2025

Author Spotlight: Advancing Research in Corneal Opacity Treatment and Regeneration
07:39

Author Spotlight: Advancing Research in Corneal Opacity Treatment and Regeneration

Published on: August 4, 2023

2.2K

Corneal Perforation Associated With Tralokinumab.

Javier García-Bardera1, Mireia García-Bermúdez1, Sergio Pernas-Martin2

  • 1Ophthalmology Department, Hospital Clinico San Carlos, Madrid, Spain.

Cornea
|June 17, 2025
PubMed
Summary

This case study documents the first instance of peripheral corneal perforation in a patient treated with tralokinumab (an IL-13 inhibitor) for atopic dermatitis. Early ophthalmologic evaluation and surgical intervention led to favorable visual recovery.

Keywords:
atopic dermatitiskeratitismonoclonal antibodyocular adverse eventperipheral

More Related Videos

Corneal Donor Tissue Preparation for Endothelial Keratoplasty
08:37

Corneal Donor Tissue Preparation for Endothelial Keratoplasty

Published on: June 12, 2012

27.8K
Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models
06:10

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

1.9K

Related Experiment Videos

Last Updated: Sep 19, 2025

Author Spotlight: Advancing Research in Corneal Opacity Treatment and Regeneration
07:39

Author Spotlight: Advancing Research in Corneal Opacity Treatment and Regeneration

Published on: August 4, 2023

2.2K
Corneal Donor Tissue Preparation for Endothelial Keratoplasty
08:37

Corneal Donor Tissue Preparation for Endothelial Keratoplasty

Published on: June 12, 2012

27.8K
Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models
06:10

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

1.9K

Area of Science:

  • Ophthalmology
  • Dermatology
  • Immunology

Background:

  • Atopic dermatitis is a chronic inflammatory skin condition.
  • Biologic therapies, including IL-13 inhibitors like tralokinumab, are increasingly used for moderate-to-severe atopic dermatitis.
  • Ocular side effects of biologic agents require careful monitoring.

Purpose of the Study:

  • To report the first documented case of peripheral corneal perforation associated with tralokinumab therapy.
  • To highlight potential severe ocular complications of IL-13 targeted therapies.

Main Methods:

  • A detailed clinical examination, imaging, and systemic workup were performed.
  • Surgical management included corneal suturing and amniotic membrane grafting.
  • The patient was followed postoperatively at a tertiary hospital.

Main Results:

  • A 66-year-old woman on tralokinumab developed a spontaneous 10 mm peripheral corneal perforation.
  • Infectious, autoimmune, and traumatic etiologies were ruled out.
  • Following surgical repair and discontinuation of tralokinumab, the patient achieved complete corneal healing and improved visual acuity.

Conclusions:

  • This case represents the first reported corneal perforation potentially linked to tralokinumab.
  • Awareness of rare, vision-threatening adverse effects of biologic agents is crucial.
  • Early ophthalmologic evaluation and multidisciplinary management are essential for patients on tralokinumab.